Current treatments for Alzheimer’s focus on the symptoms, not the underlying cause of the disease. They do little to stop Alzheimer’s from developing or getting worse. Usually these treatments are used for just a short time.

This website is designed to introduce you to a new clinical research study investigating a medication that may be able to slow or halt the progression of Alzheimer’s by dissolving the tangles in the brain associated with Alzheimer’s disease. The purpose of the study is to examine the safety and effectiveness of the investigational study drug called LMTM, a second generation tau aggregation inhibitor [TAI].

The tangles were first described by Dr. Alois Alzheimer in 1906 and in 1988 it was Professor Claude Wischik and colleagues who identified that tau tangles were made of tau protein and who subsequently developed LMTM with the goal of targeting and dissolving these tangles to stop the progression of Alzheimer’s.

While other approaches have tried to halt the progression of Alzheimer’s, particularly drugs targeting the formation of ‘amyloid plaques’ in the brain, none have yet succeeded. The study sponsor, TauRx, is pleased to open this global clinical trial to test what could be the first drug aimed at halting or slowing the progression of Alzheimer’s disease.

Read on to learn more about this important clinical research study and what you can do to help make a difference – for today and tomorrow.